Gilead Sciences is exploring collaborations and leveraging WHO prequalification processes with the Pan American Health Organization.
1 report, 1 independent
Updated Sep 5
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Gilead Sciences is exploring collaborations and leveraging WHO prequalification processes with the Pan American Health Organization.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Gilead Sciences
American company
- Required regulatory filings regarding institutional holdings were made by Gilead Sciences, Inc. with the Securities and Exchange Commission on June 11, 2026.
- A pilot program is underway involving the federal government, Benue State, and Gilead Sciences, with the state participating in the drug supply management.
-
World Health Organization
United Nations agency concerned with international public health
-
Pan American Health Organization
international public health agency
Related events
- Gilead Sciences acquired Arcellx and presented priorities at a Wells Fargo conference, while also discussing submissions with the FDA and CDC.
- Executive leadership experience gained at Gilead Sciences, involving Cocrystal Pharma.
- GSK and EXEL are developing treatments for PBC, and the FDA granted accelerated approval to Gilead Sciences for related therapies.
Coverage
Newest first; wire copies grouped- Pharmaceutical TechnologyGilead Sciences advances HIV prevention with new US partnership Gilead Sciences has announced a collaboration with the US State Department and the President’s Emergency Plan for AIDS Relief (PEPFAR)